This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lopez Dupla, M. Articles by Aguado, A.G. Search for Related Content PubMed PubMed Citation Articles by Lopez Dupla, M. Articles by Aguado, A.G. Social Bookmarking                         What's this?

Transverse myelitis as a first manifestation of systemic lupus erythematosus: a case report

Department of Internal Medicine, Santa Tecla Hospital, Tarragona, Spain

M.A. Khamashta

Lupus Arthritis Research Unit, Rayne Institute, St Thomas' Hospital, London, UK

A.D. Sanchez

Department of Internal Medicine, Santa Tecla Hospital, Tarragona, Spain

F.P. Ingles

Department of Internal Medicine, Santa Tecla Hospital, Tarragona, Spain

P.L. Uriol

Department of Internal Medicine, La Paz Hospital, Madrid, Spain

A.G. Aguado

Department of Internal Medicine, La Paz Hospital, Madrid, Spain

Transverse myelitis as a first manifestation of systemic lupus erythematosus (SLE) is very uncommon. No pathognomonic clinical or biochemical characteristics exist, and therefore an early diagnosis is often difficult. Therapy with intravenous pulses of methylprednisolone and cyclophosphamide has been shown to improve the prognosis. However, morbidity and mortality rates in transverse myelitis are still high due to the fact that complications such as opportunistic infections and pulmonary embolism are still frequent causes of death. We report a woman with relapsing transverse myelitis which was the first manifestation of SLE. A good response to pulse methylprednisolone and cyclophosphamide therapy was obtained but she died later as a result of a pulmonary embolism. We conclude that intravenous pulse methylprednisolone and cyclophosphamide therapy improve the prognosis of transverse myelitis associated with SLE but that a careful follow-up is needed to avoid complications due to the illness itself or secondary to the therapy.

Key Words: transverse myelitis • pulse methylprednisolone • pulse cyclophosphamide

Lupus, Vol. 4, No. 3, 239-242 (1995)
DOI: 10.1177/096120339500400316


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Punaro, P. Abou-Jaoude, R. Cimaz, and B. Ranchin Unusual neurologic manifestations (II): posterior reversible encephalopathy syndrome (PRES) in the context of juvenile systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 576 - 579. [Abstract] [PDF]

				A. M. Torabi, R. K. Patel, G. I. Wolfe, C. S. Hughes, D. B. Mendelsohn, and J. R. Trivedi Transverse Myelitis in Systemic Sclerosis Arch Neurol, January 1, 2004; 61(1): 126 - 128. [Abstract] [Full Text] [PDF]

				A. Tourbah, A. Clapin, O. Gout, B. Fontaine, R. Liblau, F. Batteux, J.-L. Stievenart, B. Weill, C. Lubetzki, and O. Lyon-Caen Systemic Autoimmune Features and Multiple Sclerosis: A 5-Year Follow-up Study Arch Neurol, April 1, 1998; 55(4): 517 - 521. [Abstract] [Full Text] [PDF]